05/18/2022

Payer-Imposed Quantity Limits for Antiemetics: Everybody Hurts

JCO - Oncology Practice

An American Society of Clinical Oncology Journal

Antiemetics represent one of the greatest advances in modern oncology; perhaps no other intervention has improved the quality of life of people receiving anticancer therapy more than antiemetics.1 Nausea and vomiting are also dose-limiting toxicities that can prevent the intended therapy administration. Unfortunately, payer-imposed quantity limits serve as a barrier to patient access to essential medications such as antiemetics.2 In this Editorial, we describe quantity limits of antiemetics, discuss the incentives that drive them, explore potential harms they cause, and provide recommendations for improving access.  READ MORE